![Graeme Fielder](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Graeme Fielder
Geschäftsführer bei AviadoBio Ltd.
Aktive Positionen von Graeme Fielder
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AviadoBio Ltd.
![]() AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | Geschäftsführer | 04.10.2022 | - |
Corporate Officer/Principal | 01.01.2020 | 04.10.2022 |
Karriereverlauf von Graeme Fielder
Ehemalige bekannte Positionen von Graeme Fielder
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AUDENTES THERAPEUTICS, INC. | Corporate Officer/Principal | - | - |
Ausbildung von Graeme Fielder
Auckland University | Doctorate Degree |
Stanford University | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 3 |
Vereinigtes Königreich | 2 |
Neuseeland | 2 |
Operativ
Corporate Officer/Principal | 2 |
Chief Operating Officer | 1 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
AviadoBio Ltd.
![]() AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | Health Technology |
Astellas Gene Therapies, Inc.
![]() Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
- Börse
- Insiders
- Graeme Fielder
- Erfahrung